4.950USD+7.84%Mkt Cap: 9.51M USDP/E: —Last update: 2026-05-22
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that t…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap9.51M USD
Enterprise Value8.24M USD
Revenue (TTM)6.50M USD
Gross Profit-22.03M USD
Net Income (TTM)-33.38M USD
Revenue/Share3.589 USD
Last Price4.950 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees23
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS0977021049
Valuation
P/E (Trailing)—
P/E (Forward)-0.02
PEG—
EV/EBITDA-0.28
EV/Revenue1.27
P/S1.36
P/B0.44
EPS (TTM)-16.40
EPS (Forward)-254.96
52W Range
3.91030% of range7.350
52W High7.350 USD
52W Low3.910 USD
Profitability
Gross Margin0.00%
Oper. Margin-29234.62%
EBITDA Margin0.00%
Profit Margin-433.74%
ROE-125.92%
ROA-58.81%
Growth
Revenue Growth-97.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-39.85M USD
CapEx (TTM)72.00K USD
FCF Margin-322.87%
FCF Yield-220.60%
Net Debt-584.00K USD
Net Debt/EBITDA0.02
Balance Sheet
Debt/Equity0.87
Current Ratio3.51
Quick Ratio3.12
Book Value/Sh10.32 USD
Cash/Share11.91 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateJun 9, 2025
Analyst Consensus
Rating2.0 (Buy)
Target (Mean)29.00 USD
Target Range5.000 USD – 75.00 USD
# Analysts3
Ownership
Shares Out.1.92M
Float1.77M
Insiders7.10%
Institutions28.86%
Short Interest
Short Ratio0.3d
Short % Float0.36%
Short % Out.0.36%
Shares Short7.00K
Short (prev mo.)4.99K
Technical
SMA 504.662 (+6.2%)
SMA 2005.194 (-4.7%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)30.33K
Avg Vol (10d)37.36K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—